Table 1 The baseline characteristics of the two groups of patients

Age,years,n(%)

1.295

0.255

 ≤ 75

37(52.1%)

18(60.0%)

19(46.3%)

 > 75

34(47.9%)

12(40.0%)

22(53.7%)

Gender,n(%)

0.19

0.663

 Male

47(66.2%)

19(63.3%)

28(68.3%)

 Female

24(33.8%)

11(36.7%)

13(31.7%)

ECOG status,n(%)

0.024

0.878

 0

49(69.0%)

21(70.0%)

28(68.3%)

 1

22(31.0%)

9(30.0%)

13(31.7%)

Tobacca use,n(%)

0.415

0.52

 Current or former

41(57.7%)

16(53.3%)

25(61.0%)

 Never

30(42.3%)

14(46.7%)

16(39.0%)

Hematuria,n(%)

0.019

0.89

 Yes

55(77.5%)

23(76.7%)

32(78.0%)

 No

16(22.5%)

7(23.3%)

9(22.0%)

Tumor size,n(%)

2.011

0.156

 ≤ 3

33(46.5%)

11(36.7%)

22(53.7%)

 > 3

38(53.5%)

19(63.3%)

19(46.3%)

Grade,n(%)

0.102

0.617

 High

68(95.8%)

29(96.7%)

39(95.1%)

 Low

3(4.2%)

1(3.3%)

2(4.9%)

Pathological stage,n(%)

0.256

0.914

 T2

24(33.8%)

11(36.7%)

13(31.7%)

 T3

44(62.0%)

18(60.0%)

26(63.4%)

 T4

3(4.2%)

1(3.3%)

2(4.9%)

Lymph node metastasis,n(%)

0.706

0.401

 pN0

64(90.1%)

26(86.7%)

38(92.7%)

 pN+

7(9.9%)

4(13.3%)

3(7.3%)

Location,n(%)

0.665

0.415

 Renal pelvis

30(42.3%)

11(36.7%)

19(46.3%)

 Ureter

41(57.7%)

19(63.3%)

22(53.7%)

Comorbidity

2.545

0.111

 number,n(%)

47(66.2%)

23(76.7%)

24(58.5%)

 ≤ 2

24(33.8%)

7(23.3%)

17(41.5%)

 > 2

eGFR,ml/min,n(%)

1.033

0.309

 < 60

31(43.7%)

11(36.7%)

20(48.8%)

 ≥ 60

40(56.3%)

19(63.3%)

21(51.2%)